Osteoporosis drug showdown: alendronate vs teriparatide in new Follow-Up trial
NCT ID NCT06264609
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 40 adults with osteoporosis who already completed a year of treatment with either Alendronate or Teriparatide. In this follow-up, participants will switch to the other drug for another year to see which works better for bone loss. The goal is to find a more personalized way to treat age-related bone loss.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kentucky
Lexington, Kentucky, 40536, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can discarded bone reveal the secrets to stronger bones?
- Could a common diabetes drug weaken your bones?
- A tastier calcium chew might boost bone Health—But does it work?
- Exercise program aims to steady the stance of osteoporosis patients
- Can a Bone-Strengthening infusion given right after hip surgery prevent a second break?
- Can a single dose of zoledronic acid safely treat bone loss in dialysis patients?